The Academy of Managed Care Pharmacy (AMCP) Foundation and its partners announced the top schools and colleges of pharmacy in its 21st Annual National Student Pharmacist P&T Competition. The competition convened student pharmacists from around the country to develop a formulary drug monograph and discuss how managed care pharmacy tools could be used to encourage adherence to evidence-based guidelines.
The Academy of Managed Care Pharmacy (AMCP) and AMCP Foundation recognized a group of leaders who have contributed significantly to the profession of managed care pharmacy in a special session during AMCP 2021. There were ten awards presented during the April 15, 2021 session.
AMCP has selected Drake Reiter, PharmD, RPh, as its 2021–2022 Executive Fellow in Health Care Association Leadership. This year-long training program provides a rich, in-depth learning experience for pharmacists interested in a career in health care association leadership or managed care pharmacy.
AMCP strongly believes that our PBM members are key to developing credible, evidence-based education at our national meetings and other educational activities, and we will continue to include these members on our Educational Affairs Committee and as valued faculty.
Forum participants examined the challenges of racial health disparities, including institutional barriers to access, a lack of trust in the health care system within underserved communities, the inflexibility of benefits within an antiquated system, gaps in data acquisition and reporting, and lack of cultural competency in the health care system. After deliberating the complexities of the issues and challenging each other on authentic, real-world actions, participants suggested the some strategies as the first steps to bring about equity within health care.
AMCP congratulates Dr. Vivek Murthy on his confirmation as the U.S. Surgeon General and Dr. Rachel Levine on her confirmation as Assistant Secretary of Health. Each brings a wealth of experience that will serve the American people well and help ensure more people get the health care they need. Read the full statement.
Last week, more than 30 experts representing payers, pharmacists, integrated delivery systems, health economists and analysts, patient advocates, academicians, pharmaceutical manufacturers, and other key decision-makers in the managed care setting convened virtually for AMCP’s Partnership Forum “Biosimilars: Policy, Practice, and Post-Marketing Surveillance to Support Treatment and Coverage Decisions” to identify key actions that support the use and development of biosimilars in the U.S. health care system.
AMCP Foundation recognizes Montrell Taylor, 2021 PharmD Candidate at Howard University College of Pharmacy, for his successful completion of the Genentech Evidence for Access Summer Internship Program.
AMCP Foundation proudly recognizes two student pharmacists who recently completed the Managed Care: Oncology Summer Internship program with the generous support of Pfizer, Inc.’s US Oncology Organized Customer Team.
AMCP Foundation recognizes two student pharmacists from the University of Southern California and University of Washington for the successful completion of the Specialized Summer Internship Program in Health Outcomes, sponsored by AbbVie, Inc.
Today, the Administration released a final rule, Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals, along with an interim final rule, Most Favored Nations (MFN) Model. In response, AMCP CEO Susan A. Cantrell, RPh, CAE, released the following statement.
Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; pharmacies and pharmacists across all practice settings, including health systems and hospitals, community, specialty, and managed care; supermarkets; wholesalers; pharmaceutical quality standard developers; employers and other health plan sponsors; health insurance providers; and pharmacy benefit managers, released guiding principles for the safe efficacious development, distribution, and allocation of vaccine(s) to achieve mass immunization against the coronavirus (COVID-19).